Open-label Study of Neuraminidase Inhibitor Treatment in STEMI Patients

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 382 participants.

Also called NCT04684498

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 382 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04684498
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04684498. Randomized; no masking; primary purpose treatment. Start 2020-03-01 (actual); primary completion 2023-06-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Open-label Study of Neuraminidase Inhibitor Treatment in STEMI Patients
Condition
ST Elevation Myocardial Infarction
Condition
STEMI
Intervention (Drug)
Oseltamivir phosphate capsules
Lead sponsor
Tongji Hospital (class: other)

Record details

Record id
cardio:ct-nct04684498
Content hash
886094b7c4b4f3646fa2ab93ecccfdc1e3f5d0363ebc7bba9baf256dd4835f0a